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Introduction
Albumin administration for the treatment of critically
ill patients is controversial, although it has been widely
used by clinicians for more than half a century. A
Cochrane review showed an increased rate of mortality
in patients treated with albumin administration after a
meta-analysis of 30 randomized controlled trials includ-
ing 1,419 randomized patients.1 However, when more
studies were added into the meta-analysis, the adverse
effect of albumin administration on mortality disap-
peared.2 The reason for this was due to the inclusion
criteria in studies being diverse and the infused fluid
regimens varying widely among the included trials. A
recent randomized controlled study (Saline versus
Albumin Fluid Evaluation study) provided more data
on 7,000 patients who were randomized to receive
either albumin or normal saline as resuscitation fluid;
the results showed that there was no significant differ-
ence in outcome between the 2 groups.3
Hypoalbuminemia in Acute Illness
The normal serum concentration of albumin in healthy
adults is approximately 3.5–5.0 g/dL. Hypoalbumine-
mia is quite common in critically ill patients, especially
in severe sepsis. Increased mortality, morbidity, and
prolonged ICU or hospital stay in acutely ill patients
with hypoalbuminemia is well recognized.4,5 The asso-
ciation between hypoalbuminemia and poor outcomes
has caused most clinicians to administer exogenous
albumin for their hypoalbuminemic patients.6
Several mechanisms may explain the protective
effects of serum albumin. Serum albumin can maintain
physiologic homeostasis. At reduced albumin levels,
homeostatic functions may be impaired, resulting in the
development or progression of pathologic processes
and poor outcome. The biologic actions of albumin
have not been fully delineated. One action is the ability
to maintain normal colloid osmotic pressure; reduction
in osmotic pressure may cause edema.
The inflammatory processes during acute illness may
induce hypoalbuminemia, and inflammatory mediators
can increase vascular permeability to promote escape
of circulatory albumin into the extravascular space. 
C-reactive protein is one marker of inflammation that
has been proposed to account for the association
between hypoalbuminemia and poor outcome.7 It is
possible that certain undetectable derangements in
patients’ inflammatory response may also cause the
hypoalbuminemic effect.
Because of its high frequency in pathologic condi-
tions, hypoalbuminemia is interpreted as a normal
compensatory mechanism not requiring intervention.
Albumin redistribution into the interstitial space may
provide protection from the oxidative stress affect-
ing extravascular tissues during disease states. Hypo-
albuminemia-related reductions in osmotic pressure,
intravascular antioxidative reserve, binding activity,
and other protective effects of albumin in the plasma
compartment still have difficulty to be a beneficial
adaptation.
Benefit of Albumin Administration in
Patients with Hypoalbuminemia 
There is not enough evidence to show that adminis-
trating human albumin to replace the lost blood in
critically ill or injured patients will improve survival
when compared to giving normal saline. Trauma, burns
or surgery can cause patients to lose large amounts of
blood. Fluid resuscitation is used to help patients restore
circulatory volume and hopefully reduce the risk of
mortality. However, the results of previous clinical trials
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failed to show that albumin can reduce the risk of
mortality. In addition, albumin is very expensive, and
it may be better to use cheaper alternatives such as
normal saline for fluid resuscitation.
Two types of evidence may support the adequacy of
albumin replacement therapy for hypoalbuminemia.
The first is the results from multivariate analysis of
cohort study data collected for the purpose of evalu-
ating the relationship between albumin level and out-
come specifically in acutely ill patients, and the other is
the findings of controlled trials evaluating the effects of
correcting hypoalbuminemia on morbidity. Such evi-
dence has not previously been systematically reviewed.
In one included cohort study of 9,352 cardiac 
surgical patients,8 hypoalbuminemia was predictive of
postoperative infection, and ICU stay increased more
than fivefold in patients who developed infections
(13.4 ± 20.1 days vs. 2.5 ± 3.8 days; p < 0.001). In
another included cohort study of elderly hospital-
ized patients, hypoalbuminemia was associated with
increased risk for delirium.9 Mean hospital stay was
23.7 days for patients with delirium compared with
13.6 days for non-delirious patients. A morbidity ben-
efit due to albumin therapy, if demonstrable, might
improve the overall costs of care. Significant edema in
patients with hypoalbuminemia may limit their mobility
and prolong hospitalization. Savings resulting from a
reduced morbidity rate may exceed the acquisition cost
of albumin.
Use of Albumin in Patients with 
Severe Sepsis
Administration of purified albumin is clearly effective
in raising serum albumin levels. Even in patients 
with severe sepsis, a pathologic condition marked by
increased vascular permeability, administration of
albumin may produce a prompt and sustained rise in
serum albumin concentration.10 If serum albumin does
indeed exert a protective effect, then exogenous albu-
min administration might benefit hypoalbuminemic
patients. Furthermore, even if albumin level did reflect
other upstream pathologic processes, albumin admin-
istration might be effective as a downstream inter-
vention to interrupt the events culminating in poor
outcome.
Chou et al11 analyzed 143 patients with severe
sepsis due to secondary peritonitis and found that albu-
min administration might reduce 28-day mortality in
patients whose baseline albumin level was ≤ 20 g/L.
They also concluded that albumin administration had
no effect on patients whose baseline serum albumin
level was > 20 g/L. Although their analysis was a ret-
rospective study, they narrowed down the causes of
patients with secondary peritonitis with sepsis. In addi-
tion, they found that albumin administration was
helpful for these septic patients with severe hypoalbu-
minemia (≤ 20 g/L). Their findings provide a clue for
clinicians to make decisions on albumin administration
for patients with severe sepsis.
Future Prospects
Further prospectively well-designed, adequately pow-
ered, controlled clinical trials are necessary to determine
whether or not correcting hypoalbuminemia is bene-
ficial for acute illness. Before the results of such future
studies, there does appear to be a coherent rationale
for albumin administration therapy and no compelling
basis to withhold albumin if it is clinically appropriate
in severely hypoalbuminemic patients.
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